Corvus Pharmaceuticals, Inc. Warrants Not Settleable in Cash, Fair Value Disclosure
Corvus Pharmaceuticals, Inc. (CRVS) had Warrants Not Settleable in Cash, Fair Value Disclosure of $8.93 million as of 2024-09-30, per its 10-Q filed 2024-11-12.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:WarrantsNotSettleableInCashFairValueDisclosure · last filed 2024-11-12
- 2024-09-30: Warrants Not Settleable in Cash, Fair Value Disclosure $8.93M.
| Period end | Warrants Not Settleable in Cash, Fair Value Disclosure |
|---|---|
| 2024-09-30 | $8.93M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |